CureVac N.V. (CVAC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 14.93 |
| Open | 15.09 |
| Bid | 14.41 x 1300 |
| Ask | 15.39 x 1200 |
| Day's Range | 14.58 - 15.36 |
| 52 Week Range | 12.90 - 76.22 |
| Volume | |
| Avg. Volume | 628,132 |
| Market Cap | 2.735B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.87 |
| Earnings Date | Nov 18, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.85 |
- ACCESSWIRE
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.
- Simply Wall St.
What Type Of Shareholders Own The Most Number of CureVac N.V. (NASDAQ:CVAC) Shares?
The big shareholder groups in CureVac N.V. ( NASDAQ:CVAC ) have power over the company. Insiders often own a large...
- ACCESSWIRE
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
* Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer * Frame's platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigensTÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicine
